Table 2. Women with elevated CRP and/or AGP levels during pregnancy, N = 1332.
| SP | DP | DP+AZ | Overall | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | n | (%) | ||
| Enrolment (Week 16–28) | Elevated CRP | 155 | (34.9) | 163 | (36.7) | 157 | (35.4) | 475 | (35.7) |
| Elevated AGP | 130 | (29.3) | 148 | (33.3) | 139 | (31.3) | 417 | (31.3) | |
| Visit 3 | Elevated CRP | 70 | (19.3) | 59 | (15.9) | 52 | (14.2) | 181 | (16.4) |
| Elevated AGP | 38 | (10.5) | 34 | (9.1) | 32 | (8.72) | 104 | (9.4) | |
| Delivery | Elevated CRP | 273 | (75.0) | 281 | (76.2) | 264 | (73.1) | 818 | (74.8) |
| Elevated AGP | 110 | (30.2) | 124 | (33.6) | 122 | (33.8) | 536 | (32.5) | |
Elevated CRP was defined as ≥5 mg/L and elevated AGP was defined as ≥ the top quartile of all measured levels (≥ 0.345 g/L) [15, 17]. Visit 3, third treatment with IPTp 24–36 gestation weeks (gw). 1332 women had AGP and/or CRP measured, however only 1319 of these had relevant clinical data to be included in the final analysis.